2C (left exhibit) shows expression of high luciferase activity in untreated control C2 VHL−/− transfectant cells, which showed a trend towards suppressed luciferase activity in hypericin-treated C2 VHL−/− cells by approximately 40%, suggesting that hypericin tends to interfere with VEGF promoter activation in C2 VHL−/− cells, however the differences did not reach statistical significance ( P = 0.06, Mann Whitney test).
← all excerpts
Degradation of HIF-1alpha under hypoxia combined with induction of Hsp90 polyubiquitination in cancer cells by hypericin: a unique cancer therapy.
1
—
—